An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: Similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures

Rheumatology

Volumn 47, Issue 3, 2008, Pages 345-349

  Pincus, T ^a   Bergman, M J ^b   Yazici, Y ^a   Hines, P ^c   Raghupathi, K ^c   Maclean, R ^c  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b Taylor Hospital   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Abatacept; Clinical trials; DAS; Patient index; RAPID

Indexed keywords

ABATACEPT; METHOTREXATE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; DRUG RESPONSE; FUNCTIONAL STATUS; HUMAN; INTERMETHOD COMPARISON; JOINT SWELLING; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3; SCORING SYSTEM; SELF REPORT;

ACTIVITIES OF DAILY LIVING; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EVALUATION STUDIES AS TOPIC; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOCONJUGATES; INFLAMMATION; MALE; MEDICAL RECORDS; METHOTREXATE; MULTICENTER STUDIES AS TOPIC; PAIN MEASUREMENT; PATIENT PARTICIPATION; PATIENT SATISFACTION; PHYSICIANS; PROBABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANGE OF MOTION, ARTICULAR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 39449099665     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem364     Document Type: Article

References (33)

1. Goldsmith CH. Smythe HA, Helewa A. Interpretation and power of pooled index. J Rheumatol 1993;20:575-8.
2. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical; trials. Arthritis Rheum 1993;36:729-40.
3. Tugwell P, Boers M. OMERACT Committee. Proceedings of the OMERACT Conferences on outcome measures in rheumatoid arthritis clinical trials, Maastrict, Netherlands. J Rheumatol 1993;20:527-91.
4. Boers M, Tugwell P, Felson DT et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 21(Suppl 41):86-9.
5. van der Heijde DMFM, van't Hof MA, van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
6. van der Heijde DMFM, van't Hot MA, van Riel PLCM, van de Putte LBA. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
7. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp, Rheumatol 2005;23:S100-8.
8. Pincus T. The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol 2006;33: 834-7.
9. Wolfe F, Pincus T, Thompson AK, Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Care Res 2003;49:59-63.
10. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2.
11. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994;21:1227-37.
12. Pincus T. Laboratory tests in rheumatic disorders. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby International, 1997;10.1-10.8.
13. Fries JF, Spitz P. Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
14. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities ef daily living and psychological status in the patient friendly health assessment questionnaire formal. Arthritis Rheum 1999;42:2220-30.
15. Pincus T, Strand V, Koch G et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) on the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003;48:625-30.
16. Pincus T, Amara I, Koch GG. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: Lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum 2005;52:1031-6.
17. Pincus T, Chung C, Segurado OG, Amara I, Koch GG. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006;33:2146-52.
18. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies and clinical trials: The patient activity scale (PAS/PAS-II). J Rheumatol 2005;32:2410-5.
19. Kremer JM, Genant HK, Moreland LW. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006;144:865-76.
20. Genovese MC, Becker JC, Schiff M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha Inhibition. N Engl J Med 2005;353:1114-23.
21. Prevoo MLL, van' Hof MA, Kuper HH. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with meumatoid arthritis. Arthritis Rheum 190;38:44-8.
22. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
23. Tugwell P, Wells G, Strand V et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000;43:506-14.
24. Pincus T, Amara I, Segurado-OG, Bergman MJ, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab Imm control treatments in rheumatoid arthritis clinical trials. J Rheumatol 2007, Nov 15; [Epub ahead of print].
25. Fuchs HA, Brooks RH, Callahan LF, Pincus T. A siimplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989;32:531-7.
26. Lewis PA, O'Sullivan MM, Rumfeld WR, Coles EC, Jedsop JD. Significant changes in Ritchie scores. Br J Rheumatol 1988;27:32-6.
27. Hart LE, Tugwell P, Buchanan WW, Norman GR, Grace EM, Southwell D. Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol 1985;12:716-7.
28. Thompson PW, Hart LE, Goldsmith CH, Spector TP, Bell MJ, Ramadan MF. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis. patient, order and observer variation. J Rheumatoid 1991;18:661-5.
29. Klinkhoff AV, Bellamy N, Bornbardier C et al. An experiment in reducing-interobserver variability of the examination for joint tenderness. J Rheumatol 1988;15:492-4.
30. Scott DL, Choy EHS, Greeves A et al. Standardising joint assessment in rheumatoid arthritis. Clin. Rheumatol 1996;15,579-82.
31. Brown AK, Wakefield RJ, Conaghan PG, Karim Z, O'Connor PJ. Emery P. New approaches to imaging early inflammatory arthritis. Clin Exp Rheumatol 2004; 22:S18-25.
32. Smolen JS. Breedveld FC, Schiff MH et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-67.
33. Stucki G, Liang MH, Stucki S, Brühlmann P, Michel BA. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis Rheum 1995;38:795-8.